Overview
McDermott Will & Schulte advised H.A.C. Pharma, a French pharmaceutical company, on the acquisition, from Roche, of worldwide rights (excluding the United States) to the drug ESBRIET® (Pirfenidone), used to treat idiopathic pulmonary fibrosis (IPF) in adults.
This transaction enables H.A.C. Pharma to strengthen its position in the rare disease market and accelerate its international development.
The McDermott Will & Schulte team on this transaction included:
Health & Life Sciences Transactions
- Emmanuelle Trombe, Partner
- Anne-France Moreau, Partner
- Caroline Noyrez, Associate
Corporate
- Henri Pieyre de Mandiargues, Partner
- Sophie Lafay, Counsel
Financing
- Stanislas Chenu, Associate
- Hugo Lamour, Associate
- Clarisse de Roux, Associate
IP
- Charles de Raignac, Counsel
- Emie Paganon, Associate
Tax
- Come de Saint Vincent, Partner
- Paul-Henry de Laguiche, Associate
About Us
Leading organizations turn to global law firm McDermott Will & Schulte for a better way to address legal challenges, connect with those at the forefront, and drive stronger outcomes. Working across more than 20 offices globally, our 1,750+ lawyers act on data-driven insights, deep relationships, and unmatched industry experience to deliver on our commitment of Always Better.